The final version of the European Union (EU) good manufacturing practice (GMP) Annex 1 took effect in August 2023, advocating automated quality control (QC) technologies as a means of minimizing risk from microbial, particulate, and pyrogen contamination. Developers and makers of sterile pharmaceuticals can expect an array of new compliance challenges, not only in Europe but eventually in the United States.